NewsRoom Articles - Page 16 of 23

FridayOct 08, 2021 1:39 pm

FingerMotion Inc. (FNGR): A Future Anchored in Mobile Products Research and Development

FingerMotion’s R&D expenditure has been gradually increasing quarter over quarter and year on year, representing its focus on the development of innovative mobile payment and communication products for over 1/2 million users in China The company’s Big Data Insights division, Sapientus, which has accounted for most of the R&D expenditure so far, has been several years in the making FingerMotion is looking to establish a collaborative lab with partners to run as a joint research and analytics hub In March 2020, FNGR set aside resources dedicated to the R&D of an RCS platform A look at several of the recent…

ThursdaySep 30, 2021 10:45 am

Communications Tech and Data Services Provider FingerMotion Inc. (FNGR) Building Strong IP in China’s Large Insurance Market

FingerMotion Inc., has become a provider for China’s booming e-commerce market with rich communication services (“RCS”) and big-data insights, developing its Sapientus database as a solution for clients’ predictive services needs In addition to its SMS, MMS and mobile top-up business, FingerMotion’s focus on adapting Sapientus to the needs of the insurance industry are driving revenues to new records each quarter In China, insurance is compulsory to protect certain societal needs, such as pensions, medical care, employment (and unemployment), and maternity care, creating a ready market for insurance providers The Sapientus platform creates proprietary matrices for assessing consumer risk potential…

MondaySep 27, 2021 10:34 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leading the Way in Early Cancer Detection Space

Up to 50% of cancer is preventable, while other types can be detected or treated early, often resulting in complete remission for patients AnPac Bio-Medical Science Co., Ltd. uses blood-based testing to detect many types of cancer (multi-cancer tests) and pre-cancer diseases, predicting its potential to occur in the future Company’s proprietary CDA technology is powered by a database of over 220,000 clinical and general population test samples and cases and leverages a proprietary algorithm to generate personalized cancer screening Its follow-up study on multi-cancer risk assessment tests is believed to be the largest on-going study which has demonstrated its…

ThursdaySep 23, 2021 9:21 am

Infobird Co., Ltd (NASDAQ: IFBD) Signs Service Contract with a Global Leading Retail Brand

On August 3, 2021, Infobird signed a service contract with a subsidiary of a global leading retail brand The brand is a Fortune 500 retail and consumer product company and a leader in its sector, with operations in over 80 countries around the world It hopes that through this contract it will capitalize on Infobird’s intelligent quality inspection to improve its customer service system within the Chinese market This move demonstrates Infobird’s commitment to improving what it offers and successfully expanding into the market of retail and consumer product companies On August 3, 2021, Infobird (NASDAQ: IFBD) announced that it…

WednesdaySep 22, 2021 1:07 pm

FingerMotion Inc. (FNGR) Poised to Lead a Post-Pandemic Insurance Industry Renaissance in China

A 2020 Deloitte China report noted that big data will be vital in ensuring insurance survive for longer post-pandemic and accelerate their transformation towards excellence Big data is instrumental in facilitating greater product innovation and pricing accuracy for insurers Through its Big Data Insights division (Sapientus), FingerMotion appears well positioned as an ideal partner for insurers looking to implement Deloitte’s proposals The China Banking and Insurance Regulatory Commission recently scrapped the 51% cap on foreign ownership, setting the stage for potential growth of the country’s insurance sector Last year, Deloitte China released a report titled “COVID-19 and China’s Insurance Industry”…

WednesdaySep 22, 2021 9:00 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Receives College of American Pathologists Accreditation for U.S. Laboratory

AnPac Bio’s clinical laboratories are located in the U.S. and China, with a total of 142 patents issued as of March 2021 Cancer Differentiation Analysis (“CDA”) technology is AnPac Bio’s approach to early cancer detection and screening technology, with over 200,000 samples and cases to serve as a way of approaching cancer screening Company’s ownership percentage in subsidiary AnPai (Shanghai) Healthcare Management Consultant Co. Ltd. has increased from 20% to 60%, following rigorous regulatory assessments and audits With a focus on early cancer screening and detection, biotechnology company AnPac Bio-Medical Science (NASDAQ: ANPC) recently announced that its U.S. laboratory has…

ThursdaySep 16, 2021 11:43 am

Growth of China’s Tech Use Boosts Prospects for Mobile Services and Big Data Provider FingerMotion Inc. (FNGR)

U.S.-based FingerMotion is a mobile phone services and emerging big data technology company focused on the enormous prospects of China’s marketplace FingerMotion’s drive to develop its new Sapientus database IP has led to a significant agreement for providing big data to global insurance juggernaut Pacific Life’s Reinsurance division Pacific Life is among a number of outsider companies looking to enter China’s marketplace, and FingerMotion’s data is expected to help the company establish risk prediction profiles for its clientele China boasts a population of about 1.4 billion people, of whom more than half have adopted mobile phone technology during the past…

MondaySep 13, 2021 1:03 pm

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for National Medical Products Administration Registration of Early-Warning Cancer Technology with a Record 11 Tumor Types Under Formal Medical Device Product Registration

AnPac Bio-Medical Science Co., Ltd. has developed its proprietary Cancer Differentiation Analysis (“CDA”) technology to detect biophysical signals as an alternative early disease indicator to blood-based biomarker testing for cancer The company has laboratories and R&D facilities in China equipped for CDA testing and cancer biochemical testing, as well as a CLIA/CAP accredited laboratory in the United States AnPac Bio recently held its 2021 technical symposium in China where KOLs from major hospitals and universities discussed new technologies for cancer detection and treatment. AnPac Bio-Medical Science (NASDAQ: ANPC) is moving forward with testing and registration of its multi-cancer screening technology…

ThursdaySep 09, 2021 1:38 pm

Data Services Innovator FingerMotion Inc. (FNGR) Sees Growing Potential in China’s Insurance Market

U.S.-based data tech company FingerMotion is focused on the market potential of Chinese companies’ need for rich communication services (“RCS”) and big-data insights FingerMotion has been particularly focused on the insurance industry’s need for data analysis in recent months, particularly in light of China’s early-stage structure for credit and risk assessment among consumers FingerMotion’s Sapientus platform provides predictive services for risk assessment, spawning a landmark agreement with Pacific Life Re-insurance’s insurtech solutions in China Because China regards insurance as compulsory for sectors such as pension protection, medical care, job hazards, unemployment and maternity care, the potential for insurance services is…

WednesdaySep 08, 2021 9:30 am

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Symposium Highlights the Application of Biophysical Technology in Cancer Prevention and Treatment

AnPac Bio-Medical Science Co., Ltd. held its 2021 technical symposium, entitled “The Applications of Biophysical Technology in Cancer Prevention and Treatment” in Shanghai, China, on August 6, 2021 The symposium included attendees from various hospitals, universities, and Fortune 500 companies, including Thermo Fisher Scientific and AnPac Bio’s contract partner Roche Pharmaceuticals China A recent report from Frost & Sullivan ranked AnPac Bio at #3 in the world and 1st in China for the number of clinical samples analyzed amongst companies that offer next-generation early cancer screening and detection technology AnPac Bio-Medical Science (NASDAQ: ANPC) recently held its 2021 technical symposium…

ChineseWire provides insights and opportunities in Chinese companies.

Contact us: (512) 354-7000